ACHV · Achieve Life Sciences, Inc.

This 10-K/A is fundamentally a governance and capital structure update, not a financial performance report. The complete absence of financial metrics — including zero entries for revenue, expenses, assets, liabilities, or cash flows — is not an omission but a factual reflection: Achieve Life Sciences remains a pre-revenue, clinical-stage biopharma with no commercialized products and no income-generating operations as of FY2025. That structural reality shapes every element of the filing. Unlike operational annual reports, this document centers on how leadership, board composition, and capital stewardship are being realigned to support the singular objective of advancing cytisinicline through FDA review — a process that remains wholly dependent on external financing and regulatory outcomes, not internal financial generation.

Leadership continuity was restructured in April 2026 with Andrew Goldberg’s appointment as CEO. His background includes board service at Tarsus Pharmaceuticals and Inquis, along with dual board certification in internal medicine and clinical pharmacology — expertise directly relevant to late-stage development oversight and regulatory engagement. This shift signals a deliberate pivot toward disciplined capital stewardship focused on near-term inflection points, rather than platform expansion or early-stage discovery. Concurrently, Richard Stewart’s departure activated specific contractual terms: his separation agreement provides for full acceleration of unvested equity upon a Corporate Qualifying Termination, reinforcing how executive incentives remain tightly coupled to governance transitions and milestone proximity — not financial results.

Board evolution followed a parallel logic. New directors bring domain-specific credibility in FDA-facing development, commercial launch planning, and clinical-stage capital allocation — not broad-based corporate governance. Their collective experience reflects an intentional recalibration: the board’s mandate is now execution against defined regulatory pathways, not long-term R&D strategy. This alignment is critical because, without revenue, cash preservation and milestone discipline become the only levers for value creation. The filing’s silence on financials therefore functions as a diagnostic signal — it underscores that investor expectations must be anchored to binary events (e.g., NDA acceptance, advisory committee outcomes, approval) rather than incremental financial trends. Ultimately, this 10-K/A documents a company operating in a distinct phase of biopharma development: one where governance quality, capital efficiency, and regulatory fluency are the sole proxies for progress — and where every disclosure choice, from leadership transitions to board refreshment, is calibrated to that reality.